Rosett Max sold $1.1M of IMNM
Rosett Max (Chief Financial Officer) sold 60,000 shares of Immunome Inc. (IMNM) at $18.23 ($1.09M total) on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on insider activity, but the 10b5-1 plan framing suggests the trades were scheduled in advance, limiting fundamental interpretation.
Market read
A CFO open-market sale (10b5-1) is a modest sentiment input rather than a catalyst for repricing.
What to watch
Traders may overreact to insider sales; without additional context (e.g., total planned sales, option exercises, or concurrent buys), the signal is weak.
Background
The article is an SEC Form 4 insider transaction: CFO Rosett Max sold shares of Immunome Inc. (IMNM) in an open-market transaction.
Ticker impact
Immunome CFO Rosett Max filed an open-market sale of 60,000 shares at $18.23 on 2026-06-15 under a 10b5-1 plan.
Likely limited immediate impact; any effect is more sentiment-driven than fundamental.
The filing is a primary SEC Form 4 disclosure, but the presence of a pre-arranged 10b5-1 plan reduces interpretive weight versus unscheduled sales.
Market effects
No sector-wide read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerImmunome Inc.
Subject of the Form 4 insider sale by its CFO.
- insiderRosett Max
Chief Financial Officer who sold 60,000 shares at $18.23 under a 10b5-1 plan.